Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488786 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind
A NA study of Blindness, sponsored by Wicab.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 7
- Study locations
NCT01488786 is a NA study of Blindness that has completed, run by Wicab. The registered enrollment target is 75 participants, above the 48-participant average among 7 other Blindness trials with a reported enrollment target (56% higher). The trial reports 7 study locations across 7 states.
The verdict
NCT01488786, a NA study of Blindness, has completed, sponsored by Wicab.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess the safety of the BrainPort vision device and to demonstrate improved object recognition and word identification and ambulation with use of the BrainPort vision device in subjects who are medically documented as blind, with acuity of 20/ 5000 or worse.
Conditions Studied
Interventions
- DEVICE BrainPort Vision Device
Study Locations (7)
Florida
- Independence for the Blind of West Florida Inc. - Pensacola
Illinois
- The Chicago Lighthouse for People Who Are Blind and Visually Impaired - Chicago
Kansas
- Envision - Wichita
Louisiana
- Ochsner Clinic Foundation - New Orleans
New York
- Lighthouse International - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Other
- Canadian National Institute for the Blind - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01488786
The ClinicalTrials.gov registry entry for NCT01488786 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 7 other Blindness trials with a reported enrollment target (56% higher). The listed sponsor is Wicab, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Blindness appearing as the primary indexed condition, and to 1 intervention - of which BrainPort Vision Device is the first listed.
NCT01488786 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Florida, Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT01488786 about?
NCT01488786 is a clinical study titled "A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind". The purpose of this study is to assess the safety of the BrainPort vision device and to demonstrate improved object recognition and word identification and ambulation with use of the BrainPort vision device in subjects who are medically documented as blind, with acuity of 20/ 5000 or worse.
What is the current status of trial NCT01488786?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2011-10. Estimated completion is 2013-04.
What conditions does trial NCT01488786 study?
This clinical trial studies the following conditions: Blindness.
What interventions are being tested in trial NCT01488786?
The interventions under investigation include: BrainPort Vision Device (DEVICE).
Who is sponsoring clinical trial NCT01488786?
This trial is sponsored by Wicab, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01488786 being conducted?
This trial has 7 study locations across Florida, Illinois, Kansas, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blindness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing Tactile Aids With Blind Subjects
RECRUITING · NA
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Enhanced Tactile Memory in the Blind
COMPLETED
-
Brain Plasticity of Verbal Memory in the Blind
COMPLETED
-
Natural History Study of CEP290-Related Retinal Degeneration
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.